The global Gastroesophageal Reflux Disease (GERD) Therapeutics Market is
expected to reach USD 4.34 billion by 2025, according to a new study by Grand
View Research, Inc. The incidence of acid reflux disorder, also known as
heartburn, is rapidly increasing worldwide. Various studies state that almost
every person experiences acid reflux once in a lifetime.
The overall market has been experiencing a
downturn in terms of revenue in the past several years as the leading drugs for
GERD treatment have lost their patent protection, with their market shares now
largely consumed by over-the-counter (OTC) and generic medications. Although
loss of exclusivity of high-grossing drugs have caused a market fall-off, the
demand for acid reducing drugs due to the high prevalence and incidence levels
of GERD will prove beneficial to the industry from a commercial standpoint.
GERD is one of the commonly observed
recurrent gastrointestinal disorders worldwide. The prevalence of acid reflux
and related symptoms has increased across the globe by nearly 50% over the last
decade. This disorder not only has major effects on the health and quality of
patient lives, but also extends to the healthcare system and economy.
In addition, the occurrence of acid reflux
disease increases with age, rendering elderly people more prone to developing a
severe form of heartburn. The geriatric subset hence forms a prominent target
population for GERD therapeutics.
To request
a sample copy or view summary of this report, click the link below:
http://www.grandviewresearch.com/industry-analysis/gastroesophageal-reflux-disease-gerd-therapeutics-market
http://www.grandviewresearch.com/industry-analysis/gastroesophageal-reflux-disease-gerd-therapeutics-market
Further key
findings from the study suggest:
- Antacids have been identified as the largest drug
type segment in terms of revenue share due to their cost-effectiveness and
greater consumer accessibility
- The rising trend of self-medication in case of
heartburn is particularly responsible for the growth in sales of OTC
antacids
- Proton pump inhibitors accounted for the second
largest segment as they are the most commonly prescribed medication for
the treatment of acid reflux
- Market share of proton pump inhibitors is expected
to decline over the forecast period with the loss of patent protection of
several leading drugs, such as Nexium and Prilosec, in this segment
- North America accounted for the largest regional
market in 2016 owing to the presence of a large patient population
suffering from heartburn and the availability of OTC generics
- On the other hand, Asia Pacific is expected to grow
at a fairly high growth rate as compared to other regional markets due to
increased adoption of OTC and generic antacids along with rising
prevalence of heartburn
Grand View Research has segmented the GERD
therapeutics market on the basis of drug type and region:
GERD
Therapeutics Drug Type Outlook (Revenue, USD Million, 2014 - 2025)
- Antacids
- H2 Receptor Blockers
- Proton Pump Inhibitors (PPIs)
- Pro-kinetic agents
GERD
Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Brazil
- Middle East and Africa (MEA)
- South Africa
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
Blog: https://healthcareforecastreport.blogspot.com/
No comments:
Post a Comment